Patients with higher expression levels of SIGLEC1 often exhibit more macrophage (M0 and M2 types) infiltration and poorer survival prognosis, indicating that specific immune markers may influence the immune balance in the tumor microenvironment, thereby having a significant impact on tumor development. Here, SIGLEC1 is linked to neoplasm.